Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
18 participants
INTERVENTIONAL
2004-11-30
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy
NCT00281255
Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients
NCT00477789
A Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of an Intravenous Solution of JNJ-39588146 or Placebo in Patients With Heart Failure
NCT01120210
Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure
NCT01814319
Effect of Allopurinol on Left Ventricular Function in Children With Dilated Cardiomyopathy
NCT05193838
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators propose to study 10 healthy subjects and up to 25 with heart failure (dilated cardiomyopathy) before and after a single 300mg IV infusion of allopurinol.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Allopurinol
One time intravenous administration of Allopurinol 300 mg infused over approximately 20 minutes.
Allopurinol
intravenous infusion of allopurinol (300mg)
Placebo
One time intravenous administration of 50 ml dose of 5% dextrose infused over approximately 20 minutes.
Placebo
intravenous infusion of 50 ml dose of 5% dextrose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Allopurinol
intravenous infusion of allopurinol (300mg)
Placebo
intravenous infusion of 50 ml dose of 5% dextrose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient is willing and able to provide informed consent
* Clinical diagnosis of chronic heart failure
* Ejection fraction (EF) \< 40% by echocardiography, nuclear multigated acquisition (MUGA) or cath ventriculography
* No significant coronary disease at cardiac catheterization
* New York Heart Association (NYHA) Class I-IV symptoms
* Clinical stabilization for two weeks if following recent congestive heart failure (CHF) decompensation.
Exclusion Criteria
* Inability to lie flat for MR study
* Administration of additional investigational drugs
* Calculated creatinine clearance \< 50 mL/min
* Allergy to allopurinol
* Current gout flare
* Currently taking oral allopurinol
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Johns Hopkins University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Robert G. Weiss
Professor of Medicine and Radiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert G Weiss, MD
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins Hospital
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hirsch GA, Bottomley PA, Gerstenblith G, Weiss RG. Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts. J Am Coll Cardiol. 2012 Feb 28;59(9):802-8. doi: 10.1016/j.jacc.2011.10.895.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB: 04-10-12-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.